

Sensitivity analysis for the average treatment effect in paired observational studies

Colin B. Fogarty *

Abstract

A method for conducting a sensitivity analysis for the average treatment effect in a paired observational study is presented. It is shown that, in the limit, the power of a sensitivity analysis for the average treatment effect under a constant treatment effect model using a permutational t -test is at least as large as that when allowing for heterogeneous effects. In small samples, this need not be the case: the power of a sensitivity analysis for the average treatment effect can be larger than that of a permutational t -test. This illustrates that while absent in large samples, the apparent paradox from randomization inference described in Ding (2016) can persist in small samples in a sensitivity analysis. In the critical region of a sensitivity analysis where the allowable strength of unmeasured confounding is small (and thus is least likely to be dismissed as inconceivable by field experts), the discrepancies between inferences from the permutational t -test and for the average treatment effect allowing for heterogeneous effects are quite modest both in the limit and in small and moderate samples.

1 Introduction

In the analysis of both randomized experiments and observational studies with continuous outcome variables, it is common to assume that the treatment effect is constant for each individual when inferring the magnitude of a causal effect. This constant treatment effect model amounts to an assumption about the joint distribution of the potential outcomes under treatment and control, and hence cannot be verified through the data at hand. Unease is sometimes expressed about the strength of this assumption, particularly in the context of observational studies where findings are susceptible to bias from unmeasured confounding; see, for example Heckman et al. (2006) and the discussion and rejoinder of Rosenbaum (2002a). To address this unease, we present a new method for conducting a sensitivity analysis for the average treatment effect in a paired observational study while allowing for heterogeneous individual effects. This method naturally extends existing methods for conducting inference in a paired randomized experiment to the context of a paired observational study, allowing researchers to assess the robustness of inference on the average treatment effect to unmeasured confounding. As the average treatment effect represents the most common quantification of intervention's impact in many fields of study (Imbens, 2004), this work aims to both enable and encourage researchers to conduct sensitivity analyses when inferring treatment effects in observational studies.

*Operations Research and Statistics Group, MIT Sloan School of Management, Massachusetts Institute of Technology, Cambridge MA 02142 (e-mail: cfogarty@mit.edu)

2 A paired observational study

There are I independent matched pairs. In the i^{th} matched pair there is one individual who receives the treatment, $Z_{ij} = 1$, and one who receives the control, $Z_{ij'} = 0$, such that $Z_{i1} + Z_{i2} = 1$ for each i . These pairs are formed on the basis of observed pre-treatment covariates x_{ij} so that $x_{i1} = x_{i2}$ in each pair i ; however, individuals may differ on the basis of an unobserved covariate $0 \leq u_{ij} \leq 1$, such that $u_{i1} \neq u_{i2}$. Each individual has a potential outcome under treatment, r_{Tij} , and under control, r_{Cij} . The fundamental problem of causal inference is that the pair of potential outcomes (r_{Tij}, r_{Cij}) is not jointly observable, and hence we cannot observe the individual treatment effect $\tau_{ij} = r_{Tij} - r_{Cij}$ for any individual. Instead, we observe the response $R_{ij} = r_{Tij}Z_{ij} + r_{Cij}(1 - Z_{ij})$. See Neyman (1923) and Rubin (1974) for more on the potential outcomes framework.

Boldface will be used to represent vector quantities; for example, $\mathbf{Z} = [Z_{11}, Z_{12}, \dots, Z_{I2}]$ is the vector of length $2I$ containing the treatment assignments for all individuals. Define Ω_I as the set of 2^I possible values of $\mathbf{Z}$ under the matched pairs design. In a paired randomized experiment, randomness is modeled through the assignment vector; each $\mathbf{z} \in \Omega_I$ has probability 2^{-I} of being selected. Let $\mathcal{Z}_I$ denote the event $\{\mathbf{Z} \in \Omega_I\}$. Quantities dependent on the assignment vector such as $\mathbf{Z}$ and $\mathbf{R}$ are random, whereas $\mathcal{F}_I = \{(r_{Tij}, r_{Cij}, x_{ij}, u_{ij}), i = 1, \dots, I, j = 1, 2\}$ contains fixed quantities.

For a randomized experiment, $\pi_i = \mathbb{P}(Z_{i1} = 1 | \mathcal{F}_I, \mathcal{Z}_I) = 1/2$. In an observational study, it may be the case that $\pi_i \neq 1/2$ in pair i due to differences in u_{i1} and u_{i2} for the individuals in matched pair i of I . Regardless, the probability of an observed allocation $\mathbf{z}$ is given by

$$\mathbb{P}(\mathbf{Z} = \mathbf{z} | \mathcal{F}_I, \mathcal{Z}_I) = \prod_{i=1}^I \pi_i^{z_{i1}} (1 - \pi_i)^{1-z_{i1}},$$

and the randomization distribution for any test statistic $T = T(\mathbf{Z}, \mathbf{r}_C, \mathbf{r}_T)$ is

$$\mathbb{P}(T \geq t | \mathcal{F}_I, \mathcal{Z}_I) = \sum_{\mathbf{z} \in \Omega_I} \mathbb{1}\{T \geq t\} \prod_{i=1}^I \pi_i^{z_{i1}} (1 - \pi_i)^{1-z_{i1}}. \quad (1)$$

Without control over the assignment mechanism, the vector of probabilities $\boldsymbol{\pi} = [\pi_1, \dots, \pi_I]$ is unknown to the researcher in an observational study. Through a sensitivity analysis, one seeks to assess the robustness of a study's finding to deviations from a paired experiment caused by unmeasured confounding. A sensitivity analysis places bounds on the allowable departure from a pure randomized experiment for two individuals in the same matched pair. We use the model of Rosenbaum (1987), which controls the allowable departure from a paired randomized experiment due to unmeasured confounding through a parameter $\Gamma = \exp(\gamma) \geq 1$. In each pair i , the model relates u_{i1} and u_{i2} to π_i by

$$\pi_i = \frac{\exp(\gamma u_{i1})}{\exp(\gamma u_{i1}) + \exp(\gamma u_{i2})},$$

which implies that $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma)$. A sensitivity analysis proceeds by, for a given value of Γ , finding the allocation of treatment assignment probabilities $\boldsymbol{\pi}$ which yields the worst-case p -value in (1), thus yielding the worst-case null distribution for the desired inference. One

then iteratively increases the value of Γ until the null hypothesis can no longer be rejected. This changepoint Γ serves as a measure of the robustness of the study's findings to unmeasured confounding.

3 The average treatment effect

3.1 Definition and hypothesis testing

Define $\varphi_{i1} := r_{Ti1} - r_{Ci2}$ and $\varphi_{i2} := r_{Ti2} - r_{Ci1}$ to be the observed paired difference if $Z_{i1} = 1$ and $Z_{i1} = 0$ respectively. The treated minus control difference in pair i that is actually observed is

$$Y_i = Z_{i1}(\varphi_{i1}) + (1 - Z_{i1})\varphi_{i2}.$$

The average treatment effect in a paired experiment or observational study is defined as

$$\begin{aligned}\bar{\tau} &:= \frac{1}{2I} \sum_{i=1}^I (\tau_{i1} + \tau_{i2}) \\ &= \frac{1}{2I} \sum_{i=1}^I (\varphi_{i1} + \varphi_{i2}).\end{aligned}$$

We consider the observed paired difference $\bar{Y} = I^{-1} \sum_{i=1}^I Y_i$ as an estimator for $\bar{\tau}$, and use it henceforth as a test statistic for inference on $\bar{\tau}$; let $\bar{y}$ be the realized value of $\bar{Y}$ in any given randomization. In a purely randomized matched pairs design with $\pi_i = 1/2$, $\bar{Y}$ is an unbiased estimator of $\bar{\tau}$ (Rosenbaum, 2002b). In an observational study, proceeding as though $\pi_i = 1/2$ would represent a specious presumption. As a consequence, $\bar{Y}$ may be biased for $\bar{\tau}$. Assessing how strong the bias would have to be to alter the findings of the study is the goal of the sensitivity analysis. We now discuss existing methods for conducting a sensitivity analysis on the treatment effect $\bar{\tau}$.

If we were to assume that the treatment effect was constant across individuals, i.e. that $r_{Tij} = r_{Cij} + \bar{\tau}$ for all individuals in the study, a null hypothesis for the average treatment effect would be sharp, in that it would fix the values of (r_{Tij}, r_{Cij}) for each individual. This would facilitate the use of randomization tests to assess statistical significance, as the distribution (1) would be specified. Further, it would allow us to use the methods of Rosenbaum (2007) to conduct a sensitivity analysis. As mentioned in §1, there is disagreement as far as how innocuous the assumption of a constant treatment effect truly is. We thus seek to develop methods for a sensitivity analysis while allowing for heterogeneous effects.

In the absence of a constant treatment effect model, a null hypothesis $H_0 : \bar{\tau} = \bar{\tau}_0$ is composite, in that there are in fact infinitely many allocations for the $2I$ missing potential outcomes that satisfy the null in question. We call a set of potential outcomes consistent with a null hypothesis on the average treatment effect if it is (a) consistent with observed data, in that $Z_{i1}\varphi_{i1} + (1 - Z_{i1})\varphi_{i2} = Y_i$; and (b) in agreement with the null hypothesis, in that $\sum_{i=1}^I (\varphi_{i1} + \varphi_{i2}) = 2I\bar{\tau}_0$. The first condition recognizes that we know the true values for half of the potential outcomes

based on the observed data, while the second signifies that when testing a null hypothesis, we only consider allocations of potential outcomes where the corresponding causal parameter takes on the desired value.

Let $\mathcal{H}(\bar{\tau}_0)$ represent the set of potential outcomes satisfying conditions (a) and (b) above. As the size of a composite null hypothesis test is the supremum of the sizes of the elements of the composite null, to reject the null $H_0 : \bar{\tau} = \bar{\tau}_0$ at level α , we must reject the null for all $\{\varphi_1, \varphi_2\} \in \mathcal{H}(\bar{\tau}_0)$ at level α , where $\varphi_j = [\varphi_{1j}, \dots, \varphi_{Ij}]$. Unfortunately, the creation of an effective test for $\bar{\tau} = \bar{\tau}_0$ over this composite null is impossible without the imposition of a further restriction, a point discussed in Bahadur and Savage (1956). To illustrate, consider the following example.

Example 1 (Motivating a further restriction). Suppose without loss of generality $\bar{y} > \bar{\tau}_0$. Let m_i be the unobserved paired difference in matched set i and set m_i as

$$m_i = \begin{cases} (2\bar{\tau}_0 - \bar{y}) + I \max\{|y_i|\} & i \in \{1, \dots, I/2\} \\ (2\bar{\tau}_0 - \bar{y}) - I \max\{|y_i|\} & i \in \{I/2 + 1, \dots, I\} \end{cases}.$$

Clearly $\{\varphi_1, \varphi_2\} \in \mathcal{H}(\bar{\tau}_0)$. Yet for this allocation, under no unmeasured confounding $\mathbb{P}(\bar{Y} \geq \bar{y} | \mathcal{F}_I, \mathcal{Z}_I) > \mathbb{P}\left(\sum_{i=1}^{I/2} Z_{i1} > \sum_{i=I/2+1}^I Z_{i1} | \mathcal{F}_I, \mathcal{Z}_I\right) \rightarrow 0.5$ as $I \rightarrow \infty$. Furthermore, this probability could be made strictly larger in the corresponding sensitivity analysis.

This problem plagues not only the analysis of observational studies, but even the analysis of randomized experiments through the potential outcomes framework. In contemplating how to proceed, we now discuss, and subsequently borrow from, the standard procedure for inference on the average treatment effect in randomized experiments.

3.2 Asymptotic normality and estimating a variance upper bound

We now describe the subset of the composite null over which we will perform both inference under no unmeasured confounding and a sensitivity analysis. We initially restrict attention to elements of the composite null for which the estimator $\bar{Y}$ is asymptotically normal (sufficient conditions will be given later in this section). While this does not alleviate the problems raised in §3.2, employing asymptotic normality when conducting inference does lead to a natural additional condition to impose. Under a normal approximation and assuming no unmeasured confounding, the distributions of $\bar{Y}$ generated by different elements of $\mathcal{H}(\bar{\tau}_0)$ only differ due to their effect on the variance of $\bar{Y}$. When using the potential outcomes framework in randomized experiments, randomization inference for the average treatment effect typically proceeds by finding a consistent estimator of an upper bound on $\text{var}(\bar{Y} | \mathcal{F}_I, \mathcal{Z}_I)$, the variance of the estimated average treatment effect, and using that variance to conduct inference under a normal approximation. The performed inference is then size α with respect to allocations of potential outcomes whose resulting variance of $\bar{Y}$ falls below the obtained estimate of the upper bound. Moreover, if $\text{var}(\bar{Y} | \mathcal{F}_I, \mathcal{Z}_I)$ has a limit as $I \rightarrow \infty$, the size of inference conducted in this manner is less than or equal to α with probability 1 as $I \rightarrow \infty$. See Neyman (1923) and Ding (2016) among many for further details.

Under a matched pairs design, the variance of the average treatment effect is

$$\text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I) = I^{-2} \sum_{i=1}^I \pi_i(1 - \pi_i)(\varphi_{i1} - \varphi_{i2})^2$$

This variance is unknown not only due to the unobserved potential outcomes, but also due to the fact that the in an observational study π is unknown to the researcher. Despite this, we now show that an unbiased estimator of an upper bound on the variance can be attained in a paired observational study.

The standard variance estimator for $\bar{Y}$ in a paired experiment, based on the sample variance of the paired differences, is

$$S^2 = \frac{1}{I(I-1)} \sum_{i=1}^I (Z_{i1}\varphi_{i1} + (1 - Z_{i1})\varphi_{i2} - \bar{Y})^2.$$

The following proposition shows that S^2 is, in expectation, an upper bound on $\text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I)$ regardless of the value of π .

Proposition 1.

$$\begin{aligned} & \mathbb{E}[S^2|\mathcal{F}_I, \mathcal{Z}_I] - \text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I) \\ &= \frac{1}{I(I-1)} \sum_{i=1}^I \left(\pi_i\varphi_{i1} + (1 - \pi_i)\varphi_{i2} - \frac{1}{I} \sum_{k=1}^I (\pi_k\varphi_{k1} + (1 - \pi_k)\varphi_{k2}) \right)^2 \\ &\geq 0 \end{aligned}$$

Remark 1. If $\pi_i = 1/2$ for all i , S^2 is unbiased for $\text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I)$ if the treatment effect is constant. This agrees with the perception that a constant treatment effect yields the worst-case inference in a randomized experiment. This is no longer the case in a sensitivity analysis, where π_i may differ from $1/2$ in any matched pair i .

Let v denote the observed value of the random variable S^2 . Moving forward, we proceed with inference about allocations of potential outcomes which satisfy the following three conditions

Condition 1. $\sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 / \max_{1 \leq i \leq I} (\varphi_{i1} - \varphi_{i2})^2 \rightarrow \infty$ and there is an $\eta > 0$ such that $I^{-1} \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 > \eta$ as $I \rightarrow \infty$

Condition 2. $\{\varphi_1, \varphi_2\} \in \mathcal{H}_0(\bar{\tau}_0)$

Condition 3. $I^{-2} \sum_{i=1}^I \pi_i(1 - \pi_i)(\varphi_{i1} - \varphi_{i2})^2 \leq v$.

These conditions ensure that the worst-case distribution based on a given allocation of potential outcomes will be asymptotically normal (as will be discussed in the next section), that the composite null is satisfied, that the allocation of potential outcomes yields a variance for the estimated average treatment effect that does not exceed our estimated upper bound, and that our estimated average treatment effect is asymptotically normal. Conditions 2 and 3 can be actively enforced while conducting a sensitivity analysis as is shown in §4, while Condition 1 cannot be enforced and serves to rule out certain pathological values for the pairs of potential outcomes.

4 Sensitivity analysis for the average treatment effect

4.1 Formulating the optimization problem

Without loss of generality, suppose the estimate of the average treatment effect exceeds its null expectation at $\Gamma = 1$, i.e. $\bar{y} > \bar{\tau}_0$. Further arrange the individuals in each pair such $Z_{i1} = 1$ for ease of notation, resulting in φ_{i1} being known and φ_{i2} being unknown for each pair i . Consider the following optimization problem.

$$\begin{aligned} & \underset{\boldsymbol{\pi}, \boldsymbol{\varphi}_2}{\text{maximize}} \quad \sum_{z \in \Omega_I} \mathbb{1} \left\{ I^{-1} \sum_{i=1}^I (z_{i1} \varphi_{i1} + (1 - z_{i1}) \varphi_{i2}) \geq \bar{y} \right\} \prod_{i=1}^I \pi_i^{z_{i1}} (1 - \pi_i)^{1 - z_{i1}} & (\text{P1}) \\ & \text{subject to} \quad \sum_{i=1}^I \varphi_{i1} + \varphi_{i2} = 2I\bar{\tau}_0 \\ & \quad \sum_{i=1}^I \pi_i (1 - \pi_i) (\varphi_{i1} - \varphi_{i2})^2 \leq I^2 v \\ & \quad \frac{1}{1 + \Gamma} \leq \pi_i \leq \frac{\Gamma}{1 + \Gamma}. \end{aligned}$$

While problem (P1) encodes the desired sensitivity analysis at level of unmeasured confounding Γ and enforces Conditions 2 and 3, it is not tractable in its given form due to issues of non-smoothness and non-concavity. We now take steps to facilitate its computation. We begin by, through the following lemma, simplifying the optimization problem with respect to $\boldsymbol{\pi}$.

Lemma 1. *Suppose $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma) \forall i$. Then, $\mathbb{P}(\bar{Y} \geq \bar{y} | \mathcal{F}_I, \mathcal{Z}_I) \leq \mathbb{P}(I^{-1} \sum_{i=1}^I \tilde{Y}_i \geq \bar{y})$, where*

$$\tilde{Y}_i = \tilde{Z}_i \max\{\varphi_{i2}, \varphi_{i1}\} + (1 - \tilde{Z}_i) \min\{\varphi_{i2}, \varphi_{i1}\},$$

and $\tilde{Z}_i$ are independent and identically distributed Bernoulli random variables with expectation $\Gamma/(1 + \Gamma)$.

As a result, for any fixed values of $(\boldsymbol{\varphi}_1, \boldsymbol{\varphi}_2)$ the worst-case unmeasured confounder would attribute $\pi_i = \Gamma/(1 + \Gamma)$ if $\varphi_{i1} \geq \varphi_{i2}$, and $\pi_i = 1/(1 + \Gamma)$ otherwise. Hence, instead of optimizing over $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma)$ we can express π_i in terms of φ_{i1} and φ_{i2} , $\pi_i(\varphi_{i1}, \varphi_{i2}) = w_i/(1 + \Gamma) + (1 - w_i)\Gamma/(1 + \Gamma)$, where $w_i = \mathbb{1}\{\varphi_{i2} \geq \varphi_{i1}\}$. Furthermore, the special central limit theorem of Hájek and Šidák (1967, §V.1.2, p. 153) ensures that if Condition 1 is satisfied, the worst-case distribution of $\bar{Y}$ will be asymptotically normal. Before proceeding, we need to ensure that for any allocation of potential outcomes and true treatment assignment probabilities satisfying the constraints of Problem (P1), the corresponding worst-case allocation also satisfies the above constraints. This is indeed true, as we now demonstrate.

Lemma 2. For any $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma)$

$$\pi_i(1 - \pi_i)(\varphi_{i1} - \varphi_{i2})^2 \geq \frac{\Gamma}{(1 + \Gamma)^2}(\varphi_{i1} - \varphi_{i2})^2.$$

As a consequence, for any values of $\boldsymbol{\pi}$ and $\{\boldsymbol{\varphi}_1, \boldsymbol{\varphi}_2\}$ satisfying Conditions 1-3, the worst-case distribution based upon $\{\boldsymbol{\varphi}_1, \boldsymbol{\varphi}_2\}$ at Γ yields a variance for $\bar{Y}$ that is also less than or equal to the variance upper bound.

Employing a normal approximation to the randomization distribution in Problem (P1) as suggested by Condition 1, maximizing the p -value for the performed hypothesis test is equivalent to minimizing the standardized deviate. Combining this with Lemmas 1 and 2 allows us to consider the following simplified optimization problem.

$$\begin{aligned} & \underset{\boldsymbol{\varphi}_2}{\text{minimize}} \quad \frac{\bar{y} - I^{-1} \sum_{i=1}^I (\pi_i \varphi_{i1} + (1 - \pi_i) \varphi_{i2})}{\sqrt{I^{-2} \Gamma / (1 + \Gamma)^2 \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2}} & (P2) \\ & \text{subject to} \quad \sum_{i=1}^I \varphi_{i1} + \varphi_{i2} = 2I\bar{\tau}_0 \\ & \quad \frac{\Gamma}{(1 + \Gamma)^2} \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 \leq I^2 v \\ & \quad \pi_i = w_i / (1 + \Gamma) + (1 - w_i) \Gamma / (1 + \Gamma) \\ & \quad w_i = \mathbb{1}\{\varphi_{i2} \geq \varphi_{i1}\} \end{aligned}$$

The above problem could be formulated as an integer program through the use of a Big-M formulation; however, such formulations have notoriously weak continuous relaxations and can thus be very slow in practice for even moderately sized problems (Bertsimas and Tsitsiklis, 1997). Fortunately, such an approach is not necessary. In fact, as we now demonstrate, a solution to Problem (P1) can be attained through a procedure whose performance is independent of the sample size.

4.2 A simple procedure

Procedure 1. Suppose $I \geq 3$. For a fixed value of Γ , define p^* to be

$$p^* := 1/2 - \frac{\sqrt{\Gamma}}{1 + \Gamma} \frac{|\bar{\tau}_0 - \bar{y}|}{\sqrt{Iv}}.$$

Let $s_1 = \lfloor Ip^* \rfloor$ and $s_2 = \lceil Ip^* \rceil$. If $4I^{-1}(\bar{\tau}_0 - \bar{y})^2 \Gamma / (1 + \Gamma)^2 \leq v$, define μ_{s_k} , $k = 1, 2$, by

$$\begin{aligned} \mu_{s_k} &:= \bar{y} + 2(\bar{\tau}_0 - \bar{y}) \frac{\Gamma s_k + (I - s_k)}{I(1 + \Gamma)} \\ &+ \frac{\Gamma - 1}{(1 + \Gamma)} \sqrt{\frac{(I - s_k)s_k}{I^2} \left(\frac{(1 + \Gamma)^2}{\Gamma} Iv - 4(\bar{\tau}_0 - \bar{y})^2 \right)}. \end{aligned}$$

Otherwise, set $\mu_{s_k} = -\infty$ for $k = 1, 2$. Further define ν_{s_k} as

$$\nu_{s_k} = \begin{cases} \min \left\{ 4 \frac{\Gamma}{(1+\Gamma)^2} (\bar{\tau}_0 - \bar{y})^2, v \right\} & s_k = 0 \\ v & s_k \neq 0. \end{cases}$$

Now, define the deviate a_Γ by

$$a_\Gamma := \min_{k=1,2} \frac{\bar{y} - \mu_{s_k}}{\sqrt{\nu_{s_k}}},$$

and reject the null $H_0 : \bar{\tau} = \bar{\tau}_0$ if $1 - \Phi(a_\Gamma) \leq \alpha$, where $\Phi(\cdot)$ is the standard normal cumulative distribution function.

Theorem 1. Consider conditional probabilities of receiving the treatment $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma)$ for each matched pair, and suppose that Conditions 1-3 hold. Then,

$$\lim_{I \rightarrow \infty} \mathbb{P}(\bar{Y} \geq \bar{y} | \mathcal{F}_I, \mathcal{Z}_I) \leq 1 - \Phi(a_\Gamma).$$

That is, the deviate a_Γ is the solution to Problem (P2), which under a normal approximation yields an upper bound on the p-value for inference on the average treatment effect when conducting a sensitivity analysis at level of unmeasured confounding Γ .

Remark 2. The value $4I^{-1}\Gamma/(1 + \Gamma)^2(\bar{\tau}_0 - \bar{y})^2$ which determines whether or not $\mu_{s_k} = -\infty$ warrants further discussion. In Case 1 in §9.4, we show that for a fixed value of Γ this is the minimal possible value variance of the average treatment effect subject to $\{\varphi_1, \varphi_2\} \in \mathcal{H}(\bar{\tau}_0)$. For a given null hypothesis, it may be that at a given value of Γ there does not exist an allocation of potential outcomes satisfying Conditions 1-3, resulting in $a_\Gamma = \infty$. Here, we reject the null hypothesis with probability 1. This signifies that if the null were true, any allocation of potential outcomes satisfying the null would yield a variance for estimated average treatment effect that is larger than our estimated upper bound. That is, this suggests incompatibility of the observed data with the posited null hypothesis.

5 The impact of a constant effect on sensitivity to unmeasured confounding

5.1 A favorable reality unknown to the practitioner

Is there a substantial increase in sensitivity to unmeasured confounding when the assumption of a constant effect is dropped? We address this question both asymptotically and in small and moderate samples in the context of a scenario which is favorable to the researcher as advocated in Rosenbaum (2004) and Rosenbaum (2010, §14): the true average treatment effect, $\bar{\tau}$, is larger than the hypothesized value $\bar{\tau}_0$, and unbeknownst to the researcher there is no unmeasured confounding ($\Gamma = 1$). The practitioner is, as would be the case in reality, blind to this fact,

and hence would like to not only perform inference under the assumption of no unmeasured confounding, but also to assess the robustness of the study's findings to unmeasured confounding through a sensitivity analysis. We assume throughout §5 that the paired differences Y_i are drawn independently and identically distributed from a distribution $\Upsilon(\cdot)$ with $\mathbb{E}[Y_i^2] < \infty$. Let $\mathbb{E}[Y_i] = \bar{\tau}$ and $\text{var}(Y_i) = \sigma^2$.

5.2 Design sensitivity

In a sensitivity analysis, bias dominates variance in large samples (Rosenbaum, 2004). In fact, under mild regularity conditions there is a number, $\tilde{\Gamma}$, called the design sensitivity such that the power of a sensitivity analysis tends to 1 if $\Gamma < \tilde{\Gamma}$ and tends to 0 if $\Gamma > \tilde{\Gamma}$ as $I \rightarrow \infty$ (Rosenbaum, 2004). The design sensitivity is closely related to the Bahadur efficiency of a sensitivity analysis (Rosenbaum, 2015), and can be used as a means of appraising competing design strategies, comparing different test statistics, and assessing the impact of different assumptions within a sensitivity analysis. Larger values for $\tilde{\Gamma}$ indicate reduced sensitivity of inferences to unmeasured confounding in large samples.

In deriving an expression for the design sensitivity of Procedure 1, we make use of the following lemma.

Lemma 3. *For $\bar{\tau}_0 < \bar{\tau}$, if $4\Gamma/(1 + \Gamma)^2(\bar{\tau} - \bar{\tau}_0)^2 \leq \sigma^2$,*

$$\max_{k=1,2} \mu_{s_k} \rightarrow \bar{\tau}_0 + \frac{\sigma(\Gamma - 1)}{2\sqrt{\Gamma}}$$

in probability as $I \rightarrow \infty$.

Lemma 3 facilitates computation of the design sensitivity, as is now demonstrated.

Proposition 2. *The design sensitivity for Procedure 1 is*

$$\tilde{\Gamma}_{ate} = \frac{2|\bar{\tau}_0 - \bar{\tau}|\sqrt{\sigma^2 + (\bar{\tau}_0 - \bar{\tau})^2} + \sigma^2 + 2(\bar{\tau}_0 - \bar{\tau})^2}{\sigma^2}$$

We can now compare the design sensitivity for a test of the average treatment effect allowing for heterogeneous effects through Procedure 1 to that of a permutational t -test assuming a constant effect.

Proposition 3.

$$\tilde{\Gamma}_{cons}/\tilde{\Gamma}_{ate} \geq 1,$$

where $\tilde{\Gamma}_{cons}$ is the design sensitivity for inference under a constant treatment effect model using a permutational t -test on the adjusted paired differences $Y_i - \bar{\tau}_0$. That is, the design sensitivity for the permutational t -test assuming a constant treatment effect at least as large as that for a test on the average treatment effect allowing for heterogeneous effects.




Figure 1: Design sensitivity for the permutational t -test (solid) and Procedure 1 for the average treatment effect (dashed) as a function of the effect size, measured in units of standard deviations.

Proposition 3 demonstrates that the design sensitivity for inference conducted under the assumption of a constant effect will be at least as large as those conducted without assuming a constant effect for any values of $|\bar{\tau} - \bar{\tau}_0|$ and σ^2 . The magnitude of the discrepancy between inference with and without assuming a constant effect depends crucially on these two quantities. As an illustration of this dependence, Fig. 1 shows the design sensitivity for tests with and without assuming a constant effect as a function of $|\bar{\tau} - \bar{\tau}_0|/\sigma$ when $\Upsilon(\cdot)$ is a normal distribution with mean $\bar{\tau}$ and variance σ^2 . The results indicate that for large treatment effect sizes the difference in design sensitivities can be substantial, while for smaller treatment effects, the differences are less noticeable.

There is a reassuring element of these results. For studies with small treatment effects, only a small amount of bias is required to overturn the study’s findings, and this amount of bias may be plausible in the eyes of field experts. In such studies, the difference in reported insensitivity to unmeasured confounding assuming there is a constant effect (as is commonly done) and allowing for heterogeneous treatment effects is likely to be small. Stated another way, for small values of Γ the results assuming and not assuming a constant effect are unlikely to yield materially different inferences. The discrepancies in the sensitivity analyses are likely to be greatest if there truly is a strong treatment effect, but that it is thought by field experts that a large degree of unmeasured confounding may be plausible (i.e. that Γ may be large).

5.3 Power of a sensitivity analysis

While a sensitivity analysis is bias-dominated in large samples, in small and moderate samples discrepancies in variance play a larger role in a sensitivity analysis. We now illustrate that the

observed value v in the observational study at hand used in Procedure 1 can fall below the variance used to conduct inference under a constant treatment effect model if the null is false.

In the favorable setting considered in this section, $\mathbb{E}[\mathbb{E}[S^2|\mathcal{F}_I, \mathcal{Z}_I]] = \sigma^2/I$ regardless of the null being tested and regardless of the value of Γ , with the outer expectation taken over $\mathcal{F}_I$. Yet suppose we instead assume a constant treatment effect model, $H_c : r_{Tij} = r_{Cij} + \bar{\tau}_0$ for all i, j , and that we use the average of the adjusted paired differences $A_i = Y_i - \bar{\tau}_0$ as a basis for inference. Under this model, the variance of the worst-case deviate for $\bar{A}$ at level of unmeasured confounding Γ is given by $\text{var}(\bar{A}|\mathcal{F}_I, \mathcal{Z}_I, H_c) = 4I^{-2}\Gamma/(1+\Gamma)^2 \sum_{i=1}^I (Y_i - \bar{\tau}_0)^2$ (Rosenbaum, 2007). Taking expectation over $\mathcal{F}_I$, we have that $\mathbb{E}[\text{var}(\bar{A}|\mathcal{F}_I, \mathcal{Z}_I, H_c)] = 4I^{-1}(\sigma^2 + (\bar{\tau}_0 - \bar{\tau})^2)\Gamma/(1+\Gamma)^2$.

If the null is true, then $\mathbb{E}[\mathbb{E}[S^2|\mathcal{F}_I, \mathcal{Z}_I]] = \mathbb{E}[\text{var}(\bar{A}|\mathcal{F}_I, \mathcal{Z}_I, H_c)]$ if $\Gamma = 1$, and the expectation of the variance under the constant effect model becomes smaller as Γ increases. On the other hand, if the null is false then the expectation of S^2 is the smaller of the two under $\Gamma = 1$, and it will continue to be so until

$$\Gamma' = \frac{2|\bar{\tau}_0 - \bar{\tau}|\sqrt{\sigma^2 + (\bar{\tau}_0 - \bar{\tau})^2} + \sigma^2 + 2(\bar{\tau}_0 - \bar{\tau})^2}{\sigma^2},$$

which is exactly the design sensitivity for Procedure 1 shown in Proposition 2. Hence, the apparent paradox in randomization inference that a test for the average treatment effect can be more powerful than a test assuming a constant treatment effect described in Ding (2016) has potential to persist in a sensitivity analysis. Whether it actually persists for a given sample size I depends on the magnitude of the increase in bias when conducting a sensitivity analysis allowing for heterogeneity through Procedure 1 relative to that of a permutational t -test assuming a constant treatment effect model, a point we now investigate through a simulation study.

We modify the simulation setting of Rosenbaum (2005), which sought to assess the role of heterogeneity reduction in reducing sensitivity to unmeasured confounding under a constant treatment effect model. In this simulation study, we hope to not only compare sensitivity analyses for the average treatment effects, but also to assess the role of heterogeneity reduction in reducing sensitivity to unmeasured confounding when a constant treatment effect model is not assumed.

In each of four simulation settings, I paired differences are drawn independently from a normal distribution with mean $\bar{\tau}$ and variance σ^2 . In each setting, we simulate 1000 data sets. For a range of values for Γ , we estimate the probability of correctly rejecting the null hypothesis of $\bar{\tau}_0 = 0$. The values for $(I, \bar{\tau}, \sigma^2)$ in the four settings are (a) $(25, 1/2, (1/2)^2)$, (b) $(100, 1/2, 1)$, (c) $(100, 1/2, (1/2)^2)$ and (d) $(400, 1/2, 1)$. The pairs of settings (a,b) and (c,d) have the same variance for the sample mean of the paired differences, $\bar{Y}$, and differ only in matched pair heterogeneity, while pairs (a,c) and (b,d) differ only in terms of sample size.

Figure 2 shows the results of this simulation study for each of scenarios (a)-(d). We look first across the rows of Fig 2, comparing (a) to (b) and (c) to (d). In each of these comparisons, the variance of $\bar{Y}$ is the same: $1/1$ for (a,b), and $1/400$ for (c,d). Nonetheless, we see that the sensitivity analyses for both the permutational t -test and the average treatment effect are more powerful in the smaller, less heterogeneous studies, (a,c), than in the larger, more heterogeneous studies, (b,d). This demonstrates that benefits of reducing heterogeneity across subjects for improving robustness to unmeasured confounding described in Rosenbaum (2005) also apply to tests for the average treatment effect while allowing for treatment effect heterogeneity.




Figure 2: Power for the permutational t -test (solid) and Procedure 1 for the average treatment effect (dashed) as a function of Γ in simulation settings (a)-(d).

For scenarios (a,c), where the mean for the paired differences is $1/2$ and the variance $(1/2)^2$, the design sensitivities are 13 for the permutational t -test yet only 5.8 for the test on the average treatment effect using Procedure 1. Despite the differences in design sensitivities, in simulation setting (a) the test for the average treatment effect is actually more powerful than the permutational t -test for all values of Γ shown. This is a reflection that the apparent paradox from randomization inference discussed in Ding (2016) can occur within the context of a sensitivity analysis in small samples. When we increase the sample size to $I = 100$, shown in plot (c), the ordering reverses itself, yet the performance for the permutational t -test remains farther from its asymptotic value and closer to the test for the average treatment effect.

The design sensitivities for scenarios (b,d), where the paired differences are normally distributed with mean $1/2$ and variance 1, are 3.5 for the test assuming a constant effect and 2.6 for the test allowing for heterogeneity. Plots (b) and (d) reflect that the design sensitivities for Procedure 1 and for the permutational t test are similar in simulation settings (b) and (d). Plot (d) further illustrates that by $I = 400$ we begin to note convergence of the power curve to a step function with the step at the design sensitivity.

6 Accommodating essential heterogeneity

In the economics literature, one argument against assuming a constant treatment effect posits the existence of “essential heterogeneity,” wherein individuals who will benefit more from a given treatment are more likely to decide to take said treatment (Heckman et al., 2006). In a paired

observational study, one formalization of essential heterogeneity is that (assuming without loss of generality that a positive treatment effect indicates a benefit) $\pi_i - (1 - \pi_i) \geq 0 \Leftrightarrow (r_{Ti1} - r_{Ci1}) \geq (r_{Ti2} - r_{Ci2})$. That is, the individual in a given matched set with the higher probability of receiving the treatment has the larger treatment effect. One might think that such a consideration would impose a further constraint on a sensitivity analysis; however, as the following proposition demonstrates, this is not the case.

Proposition 4. *The solution to Problem (P1) is also a solution under the constraint that the individual in a matched pair for whom the treatment provides a greater benefit has the higher probability of receiving the treatment.*

Hence, we can interpret the methods developed herein as providing a sensitivity analysis in the presence of essential heterogeneity. That is, the changepoint value of Γ provides an answer to the following question: given the presence of essential heterogeneity in matched pairs, how extreme would the difference in the probabilities of receiving the intervention have to be to materially alter the findings of our study?

7 An example: DNA damage in welders

As an illustration of our methodology, we revisit an observational study of Werfel et al. (1998) assessing damage to DNA from exposure to nickel and chromium among welders. Exposed welders were matched to unexposed welders according to smoking habits and age resulting in $I = 39$ matched pairs. While Werfel et al. (1998) considered many measures of DNA damage, we will restrict attention to their measurements of relative DNA elution rate through polycarbonate filters with proteinase K (ERPC+). Positive values for ERPC+ indicate increased DNA breakage. We test the null hypothesis that $\bar{\tau} = 0$ with a one-sided alternative that $\bar{\tau} > 0$. We perform inference both with and without assuming that the treatment effect is constant, and do so both under no unmeasured confounding and while increasingly allowing unmeasured confounding to affect the inference through increasing the value of Γ in a sensitivity analysis.

The average difference in ERPC+ for the 39 matched pairs in the study is 0.573. Assuming no unmeasured confounding ($\Gamma = 1$), both Procedure 1 and the permutational t -test assuming a constant effect reject the null hypothesis at $\alpha = 0.05$. Figure 3 displays the upper bounds on the one-sided p -values for a test of $\bar{\tau} = 0$ from the permutational t -test (solid line) and for the average treatment effect using Procedure 1 (dashed line). For Γ between 1 and 2.66, the upper bound on the p -value for the test of the average treatment effect through Procedure 1 is smaller than that of the permutational t -test, a possibility discussed and observed in §5.3. For $\Gamma > 2.66$ the trend reverses. The test of the average treatment effect continues to reject the null at $\alpha = 0.05$ until $\Gamma = 3.1$, while the permutational t -test does so until $\Gamma = 3.8$. A difference exists, but the difference is not extreme. As a reference point, the finding of a causal relationship between smoking and lung cancer in Hammond (1964) continues to be significant until $\Gamma = 6$, while the finding of Jick et al. (1973) of a causal relationship between coffee and myocardial infarction is overturned at $\Gamma = 1.3$.

By the duality between hypothesis tests and confidence intervals, the methods presented herein can also be used to construct one- and two-sided confidence intervals both under no




Figure 3: (Left) Upper bounds on the p -value as a function of Γ for the permutational t -test assuming a constant effect (solid) and Procedure 1 allowing for heterogeneous effects (dashed). (Right) 90% sensitivity intervals for $\bar{\tau}$ with (solid) and without (dashed) assuming a constant effect.

unmeasured confounding and within the context of a sensitivity analysis. Figure 3 shows upper and lower bounds for 90% sensitivity intervals constructed through both our test for the average treatment effect and the permutational t -test assuming a constant treatment effect. Note that the width of the intervals increase with Γ , as their width is affected by both sampling variability and bias caused by unmeasured confounding. While the intervals produced by inverting our test for the average treatment effect are symmetric, those produced by inverting the permutational t -test need not be as Fig. 3 demonstrates. The intervals produced by the permutational t -test are wider until $\Gamma = 1.07$, are narrower from $\Gamma = 1.07$ until $\Gamma = 4.30$, and return to being wider for $\Gamma > 4.30$.

8 Discussion

Our results indicate that the discrepancies between a test on the average treatment effect allowing for heterogeneous treatment effects and the permutational t -test assuming a constant effect tend to be quite modest for the values of Γ which are likely to be most relevant, i.e. those encoding smaller (and hence, less easily dismissed) strengths of unmeasured confounding. Conversely, the results demonstrate that if a critic were worried about a large degree of unmeasured confounding being present in the study, it would require a much larger treatment effect for the sensitivity analysis on the average treatment effect to yield a satisfactory answer in the critic's eyes than would be required for a test assuming a constant treatment effect.

By no means do we believe that inference on the average treatment effect should supplant inference conducted assuming a constant effect in observational studies. For example, even if the overall assumption of a constant effect were to fail due to the presence of effect modification, it may be plausible for individuals within a given subgroup defined by the effect modifiers. In this case, Hsu et al. (2013) and Hsu et al. (2015) present methods for both discovering effect modification and subsequently testing for a constant effect within subgroups defined by the effect modifiers which can substantially improve robustness against unmeasured confounding.

Furthermore, as noted in Rosenbaum (2002a, Rejoinder, §6), even if one is skeptical that the treatment effect is constant, confidence intervals for a constant treatment effect can nonetheless illustrate which constant effects are not plausible. Rather than supplanting the model of a constant treatment effect, analyses with and without said assumption may be presented in concert as a means of further elucidating evidence for the strength of a given causal effect, just as they were in §7.

9 Proofs and derivations

9.1 Proof of Proposition 1

The proof resembles that of Proposition 1 in Imai (2008). For ease of notation, we suppress conditioning on $\mathcal{F}_I$ and $\mathcal{Z}_I$ in the expectations shown in the derivation.

$$\begin{aligned}
& \mathbb{E}[S^2 | \mathcal{F}_I, \mathcal{Z}_I] \\
&= \frac{1}{I(I-1)} \left(\sum_{i=1}^I \mathbb{E}[(Z_{i1}\varphi_{i1} + (1 - Z_{i1})\varphi_{i2})^2] - I^{-1} \mathbb{E} \left[\left(\sum_{i=1}^I (Z_{i1}\varphi_{i1} + (1 - Z_{i1})\varphi_{i2}) \right)^2 \right] \right) \\
&= \frac{1}{I(I-1)} \left(\sum_{i=1}^I \pi_i \varphi_{i1}^2 + (1 - \pi_i) \varphi_{i2}^2 \right. \\
&\quad \left. - I^{-1} \sum_{k, \ell=1}^I \mathbb{E}[(Z_{k1}\varphi_{k1} + (1 - Z_{k1})\varphi_{k2})(Z_{\ell1}\varphi_{\ell1} + (1 - Z_{\ell1})\varphi_{\ell2})] \right) \\
&= \frac{1}{I^2} \left(\sum_{i=1}^I (\pi_i \varphi_{i1}^2 + (1 - \pi_i) \varphi_{i2}^2) - \frac{1}{I-1} \sum_{k \neq \ell} (\pi_k \varphi_{k1} + (1 - \pi_k) \varphi_{k2})(\pi_\ell \varphi_{\ell1} + (1 - \pi_\ell) \varphi_{\ell2}) \right),
\end{aligned}$$

where we utilize that $Z_{i1}^2 = Z_{i1}$, $(1 - Z_{i1})^2 = (1 - Z_{i1})$, $Z_{i1}(1 - Z_{i1}) = 0$, and that there is independence across pairs. We will now show that $\mathbb{E}[S^2 | \mathcal{F}_I, \mathcal{Z}_I] - \text{var}(\bar{Y} | \mathcal{F}_I, \mathcal{Z}_I) \geq 0$. To begin,

express $I^2(\mathbb{E}[S^2|\mathcal{F}_I, \mathcal{Z}_I] - \text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I))$ as

$$\begin{aligned}
& \sum_{i=1}^I (\pi_i \varphi_{i1}^2 + (1 - \pi_i) \varphi_{i2}^2 - \pi_i (1 - \pi_i) (\varphi_{i1} - \varphi_{i2})^2) \\
& - \frac{1}{I-1} \sum_{k \neq \ell} (\pi_k \varphi_{k1} + (1 - \pi_k) \varphi_{k2}) (\pi_\ell \varphi_{\ell1} + (1 - \pi_\ell) \varphi_{\ell2}) \\
& = \sum_{i=1}^I (\pi_i^2 \varphi_{i1}^2 + (1 - \pi_i)^2 \varphi_{i2}^2 + 2\pi_i (1 - \pi_i) \varphi_{i1} \varphi_{i2}) \\
& - \frac{1}{I-1} \sum_{k \neq \ell} (\pi_k \varphi_{k1} + (1 - \pi_k) \varphi_{k2}) (\pi_\ell \varphi_{\ell1} + (1 - \pi_\ell) \varphi_{\ell2}) \\
& = \frac{I}{I-1} \sum_{i=1}^I \left(\pi_i \varphi_{i1} + (1 - \pi_i) \varphi_{i2} - \frac{1}{I} \sum_{k=1}^I (\pi_k \varphi_{k1} + (1 - \pi_k) \varphi_{k2}) \right)^2.
\end{aligned}$$

This last term is simply I times the sample variance of $\{\pi_i \varphi_{i1} + (1 - \pi_i) \varphi_{i2}\}$. Hence, $\mathbb{E}[S^2|\mathcal{F}_I, \mathcal{Z}_I] - \text{var}(\bar{Y}|\mathcal{F}_I, \mathcal{Z}_I) \geq 0$, completing the proof.

9.2 Proof of Lemma 1

If $1/(1 + \Gamma) \leq \pi_i \leq \Gamma/(1 + \Gamma)$,

$\mathbb{P}(Y_i = \max\{\varphi_{i2}, \varphi_{i1}\}|\mathcal{F}_I, \mathcal{Z}_I) \leq \mathbb{P}(\tilde{Y}_i = \max\{\varphi_{i2}, \varphi_{i1}\})$. As Y_i and $\tilde{Y}_i$ only take on the values $\min\{\varphi_{i2}, \varphi_{i1}\}$ and $\max\{\varphi_{i2}, \varphi_{i1}\}$, $\tilde{Y}_i$ is stochastically larger than Y_i . The result then follows from preservation of stochastic ordering under independent convolutions.

9.3 Additional lemmas

Lemmas 4 and 5 refer to Problem (P2). Recall that $w_i = \mathbb{1}\{\varphi_{i2} \geq \varphi_{i1}\}$.

Lemma 4. *For $\sum_{i=1}^I w_i = 1, \dots, I - 2$, any feasible solution involving $\varphi_{i2} = \varphi_{i1}$ for some i has an objective value that is less than or equal to a feasible solution with $\varphi_{i2} \neq \varphi_{i1}$ for all i .*

Proof. Suppose $\varphi_{i1} = \varphi_{i2}$ and $\sum_{i=1}^I w_i = 1, \dots, I - 2$. Then, there exist two pairs, j and k , such that $\varphi_{j2} - \varphi_{j1} < 0$ and $\varphi_{k2} - \varphi_{k1} < 0$. Define $\tilde{\varphi}_{i2} = \varphi_{i2} - c$, $\tilde{\varphi}_{j2} = \varphi_{j2} + c/2$, and $\tilde{\varphi}_{k2} = \varphi_{k2} + c/2$. Note that the increase in the test statistic's expectation is at least 0, as changing φ_{i2} to $\tilde{\varphi}_{i2}$ decreases by $c/(1 + \Gamma)$, while changing φ_{j2} and φ_{k2} to $\tilde{\varphi}_{j2}$ and $\tilde{\varphi}_{k2}$ increases it by at least $(c/2 + c/2)/(1 + \Gamma)$. Hence, the numerator of the objective function decreases by at least 0.

We now ensure that the proposed change still satisfies the variance inequality. Evaluating, $(\tilde{\varphi}_{i2} - \varphi_{i1})^2 + (\tilde{\varphi}_{j2} - \varphi_{j1})^2 + (\tilde{\varphi}_{k2} - \varphi_{k1})^2 = (\varphi_{i2} - \varphi_{i1})^2 + (\varphi_{j2} - \varphi_{j1})^2 + (\varphi_{k2} - \varphi_{k1})^2 + 3c^2/2 + c(\varphi_{j2} - \varphi_{j1} + \varphi_{k2} - \varphi_{k1})$. Setting $c = (2/3)(\varphi_{j1} - \varphi_{j2} + \varphi_{k1} - \varphi_{k2}) > 0$ yields the same value for the variance constraint.

Lemma 5. *Suppose $\sum_{i=1}^I w_i = 1, \dots, I - 1$. Then, at the solution to the problem above, $\frac{\Gamma}{(1 + \Gamma)^2} \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 = I^2 v$*

Proof. For any φ_2 satisfying these constraints but where $\Gamma/(1+\Gamma)^2 \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 < I^2 v$, find i and i' such that $\varphi_{i2} \geq \varphi_{i1}$ and $\varphi_{i'2} < \varphi_{i'1}$. Define $\tilde{\varphi}_{i2} = \varphi_{i2} + c$ and $\tilde{\varphi}_{i'2} = \varphi_{i'2} - c$ with $c > 0$. Replacing φ_{i2} and $\varphi_{i'2}$ with $\tilde{\varphi}_{i2}$ and $\tilde{\varphi}_{i'2}$, the constraint imposed by the null hypothesis is still satisfied. Furthermore, the numerator of the objective function decreases by $(\Gamma - 1)/(1 + \Gamma)c$, while the denominator increases by $\Gamma/(1 + \Gamma)^2 (2c^2 + 2c(\varphi_{i2} - \varphi_{i1} + \varphi_{i'1} - \varphi_{i'2})) > 0$. The objective function is thus further minimized, and c can be chosen such that the variance constraint is still satisfied.

Lemma 6. *Consider the optimization problem*

$$\begin{aligned} & \underset{p}{\text{maximize}} \quad \bar{y} + 2 \frac{\Gamma p + 1 - p}{1 + \Gamma} (\bar{\tau}_0 - \bar{y}) \\ & \quad + \frac{\Gamma - 1}{(1 + \Gamma)} \sqrt{p(1 - p) \left(\frac{(1 + \Gamma)^2}{\Gamma} I v - 4(\bar{\tau}_0 - \bar{y})^2 \right)} \\ & \text{subject to} \quad 0 \leq p \leq 1, \end{aligned}$$

with $\bar{\tau}_0 \leq \bar{y}$ and $4(\bar{\tau}_0 - \bar{y})^2 \Gamma / (1 + \Gamma)^2 \leq I v$. The objective function is concave in p on the domain $0 \leq p \leq 1$. The maximal objective value is

$$\mu^* = \bar{\tau}_0 + \frac{\sqrt{I v}(\Gamma - 1)}{2\sqrt{\Gamma}}, \quad (2)$$

and the arg max is given by

$$p^* = 1/2 - \frac{\sqrt{\Gamma}}{1 + \Gamma} \frac{|\bar{\tau}_0 - \bar{y}|}{\sqrt{I v}}, \quad (3)$$

which is always less than $1/2$.

9.4 Proof of Theorem 1

The proof first finds a set of candidate values for the expectation and variance for the worst-case deviate (i.e., the solution to Problem 2). First, note that if $4I^{-1}(\bar{\tau}_0 - \bar{y})^2 \Gamma / (1 + \Gamma)^2 > v$, there is no feasible solution to the desired optimization problem for any value of $\sum_{i=1}^I w_i$; in this case, the worst-case expectation is set to $-\infty$ to reflect the fact that we always reject the null. Assuming this is not the case, we will first demonstrate that our search can be restricted to a set of I candidate values for the worst-case expectation μ_s , and variance, ν_s . We do so in four cases depending on the value of $s = \sum_{i=1}^I w_i$.

Case 1. $\sum_{i=1}^I w_i = 0$.

At $\sum_{i=1}^I w_i = 0$, the worst-case expectation will then be fixed, due to the constraint imposed by the null, at $\mu_0 = \bar{y} + 2(\bar{\tau}_0 - \bar{y})/(1 + \Gamma)$. Thus, minimizing the objective function is achieved

by maximizing its denominator (i.e., by maximizing the variance). To ensure feasibility, we first consider the following optimization problem (initially without the constraint that $\sum_{i=1}^I w_i = 0$).

$$\begin{aligned} & \underset{\varphi_2}{\text{minimize}} \quad I^{-2} \frac{\Gamma}{(1+\Gamma)^2} \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 \\ & \text{subject to} \quad \sum_{i=1}^I \varphi_{i1} + \varphi_{i2} = 2I\bar{\tau}_0 \end{aligned}$$

The KKT conditions require

$$2(\varphi_{i2} - \varphi_{i1}) = \lambda_1.$$

It is then clear that $\varphi_{i2} = \varphi_{i1} + C^-$ for some constant C^- . From the constraint imposed by the null we have that $C^- = 2I^{-1} \sum_{i=1}^I (\bar{\tau}_0 - \varphi_{i1})$. This value is less than zero, so C^- is also the solution to the above optimization problem with the additional constraint $\sum_{i=1}^I w_i = 0$. This yields an objective value of $4I^{-1}\Gamma/(1+\Gamma)^2(\bar{\tau}_0 - \bar{y})^2$. If this does not satisfy the variance inequality then there is no optimal solution and we set $\mu_0 = -\infty$.

Relaxing the constraint $\sum_{i=1}^I w_i = 0$ to $\varphi_{i2} \leq \varphi_{i1}$ for all i , in order to *maximize* the variance under the null we should set $\varphi_{i2} = \varphi_{i1}$ for $I-1$ of the I pairs, and set $\varphi_{i'2} = -\varphi_{i'1} + 2I\bar{\tau}_0 - \sum_{i \neq i'} 2\varphi_{i1}$ for the other pair, i' . This yields a variance of $4\Gamma/(1+\Gamma)^2(\bar{y} - \bar{\tau}_0)^2$. The value of the variance of the worst-case deviate when $\sum_{i=1}^I w_i = 0$, is then less than or equal to $\nu_0 = \min\{4\Gamma/(1+\Gamma)^2(\bar{y} - \bar{\tau}_0)^2, v\}$.

Case 2. $\sum_{i=1}^I w_i = 1, 2, \dots, I-2$.

Using Lemmas 4 and 5 we can reformulate the optimization problem as one which seeks to maximize the expectation of the average treatment effect.

$$\begin{aligned} & \underset{\varphi_2}{\text{maximize}} \quad I^{-1} \sum_{i=1}^I (\pi_i \varphi_{i1} + (1 - \pi_i) \varphi_{i2}) \\ & \text{subject to} \quad \sum_{i=1}^I \varphi_{i1} + \varphi_{i2} = 2I\bar{\tau}_0 \\ & \quad \sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 = \frac{(1+\Gamma)^2}{\Gamma} I^2 v \\ & \quad \pi_i = w_i/(1+\Gamma) + (1-w_i)\Gamma/(1+\Gamma) \end{aligned}$$

The Lagrangian of the above problem is

$$\begin{aligned} \mathcal{L} = & \sum_{i=1}^I (\pi_i \varphi_{i1} + (1 - \pi_i) \varphi_{i2}) + \lambda_1 \left(\sum_{i=1}^I \varphi_{i1} + \varphi_{i2} - 2I\bar{\tau}_0 \right) \\ & + \lambda_2 \left(\sum_{i=1}^I (\varphi_{i1} - \varphi_{i2})^2 - \frac{(1+\Gamma)^2}{\Gamma} I^2 v \right). \end{aligned}$$

Differentiating with respect to φ_{i2} and setting to zero yields for each i

$$0 = w_i \Gamma / (1 + \Gamma) + (1 - w_i) / (1 + \Gamma) + \lambda_1 - 2\lambda_2(\varphi_{i2} - \varphi_{i1}).$$

Recalling the definition of w_i , this form then implies

$$\varphi_{i2} - \varphi_{i1} = \begin{cases} \frac{\Gamma/(1+\Gamma)+\lambda_1}{2\lambda_2} & \varphi_{i2} \geq \varphi_{i1} \\ \frac{1/(1+\Gamma)+\lambda_1}{2\lambda_2} & \varphi_{i2} < \varphi_{i1} \end{cases}.$$

By Lemma 4, it must be that $C^+ := \frac{\Gamma/(1+\Gamma)+\lambda_1}{2\lambda_2} > 0$ and $C^- = \frac{1/(1+\Gamma)+\lambda_1}{2\lambda_2} < 0$. We now further simplify the optimization problem.

$$\begin{aligned} & \underset{\{C^+, C^-, \mathbf{w}\}}{\text{maximize}} \quad \bar{y} + I^{-1} \left(\frac{\Gamma C^+}{1 + \Gamma} \sum_{i=1}^I w_i + \frac{C^-}{1 + \Gamma} \sum_{i=1}^I (1 - w_i) \right) \\ & \text{subject to} \quad \sum_{i=1}^I 2\varphi_{i1} + C^- \sum_{i=1}^I (1 - w_i) + C^+ \sum_{i=1}^I w_i = 2I\bar{\tau}_0 \\ & \quad \sum_{i=1}^I (C^-)^2 \sum_{i=1}^I (1 - w_i) + (C^+)^2 \sum_{i=1}^I w_i = \frac{(1 + \Gamma)^2}{\Gamma} I^2 v \\ & \quad C^+ > 0, \quad C^- < 0, \quad \sum_{i=1}^I w_i = 1, \dots, I - 1. \end{aligned}$$

We can express the optimal C^+ and C^- as functions of $s = \sum_{i=1}^I w_i$ by

$$\begin{aligned} C_s^+ &= \frac{2I\bar{\tau}_0 - 2\sum_{i=1}^I \varphi_{i1} - C_s^-(I - s)}{s} \\ C_s^- &= \frac{4\sum_{i=1}^I (\bar{\tau}_0 - \varphi_{i1}) \frac{I-s}{s} - 2\sqrt{\left(\frac{I-s}{s}\right) \left(I \frac{(1+\Gamma)^2}{\Gamma} I^2 v - 4 \left(\sum_{i=1}^I (\bar{\tau}_0 - \varphi_{i1}) \right)^2 \right)}}{2I \left(\frac{I-s}{s} \right)}. \end{aligned}$$

The identity for C_s^+ follows trivially from the constraint imposed by the null, $\sum_{i=1}^I \varphi_{i1} + \varphi_{i2} = 2I\bar{\tau}_0$, by

$$\begin{aligned} & \sum_{i=1}^I 2\varphi_{i1} + w_i C_s^+ + (1 - w_i) C_s^- = 2I\bar{\tau}_0 \\ & \frac{2I\bar{\tau}_0 - 2\sum_{i=1}^I \varphi_{i1} - C_s^-(I - s)}{s} = C_s^+. \end{aligned}$$

To derive the expression for C_s^- , note that the variance equality gives

$$(C_s^+)^2 s + (C_s^-)^2 (I - s) = I^2 v \frac{(1 + \Gamma)^2}{\Gamma}.$$

Expressing C_s^+ in terms of C_s^- and using the quadratic formula then provides the desired relation. Further algebra then yields the following candidate values for μ_s , $s = 1, \dots, I - 2$

$$\begin{aligned} \mu_s = & \bar{y} + 2(\bar{\tau}_0 - \bar{y}) \frac{\Gamma s + (I - s)}{I(1 + \Gamma)} \\ & + \frac{\Gamma - 1}{(1 + \Gamma)} \sqrt{\frac{(I - s)s}{I^2} \left(\frac{(1 + \Gamma)^2}{\Gamma} I v - 4(\bar{\tau}_0 - \bar{y})^2 \right)}, \end{aligned} \quad (4)$$

with corresponding variances $\nu_s = v$ for $s = 1, \dots, I - 2$ from Lemma 5.

Case 3. $\sum_{i=1}^I w_i = I - 1$.

In this scenario, it could be the case that $\varphi_{i1} = \varphi_{i2}$ for $I - 1$ of I pairs, while for the other pair, pair i' , $\varphi_{i'2} = -\varphi_{i'1} + 2I\bar{\tau}_0 - \sum_{i \neq i'} 2\varphi_{i1}$. If it so happens that $\frac{\Gamma}{(1 + \Gamma)^2} \left(\sum_{i=1}^I (2\bar{\tau}_0 - 2\varphi_{i1}) \right)^2 = I^2 v$, this is a feasible solution; however, it cannot be optimal. Take $j, k \neq i'$ such that $\varphi_{j2} - \varphi_{j1} = 0$ and $\varphi_{k2} - \varphi_{k1} = 0$. Define $\tilde{\varphi}_{i'2} = \varphi_{i'2} + c$, $\tilde{\varphi}_{j2} = \varphi_{j2} - c/2$, and $\tilde{\varphi}_{k2} = \varphi_{k2} - c/2$.

We now determine whether or not the variance constraint can still be satisfied. $(\tilde{\varphi}_{i2} - \varphi_{i1})^2 + (\tilde{\varphi}_{j2} - \varphi_{j1})^2 + (\tilde{\varphi}_{k2} - \varphi_{k1})^2 = (\varphi_{i2} - \varphi_{i1})^2 + 3c^2/2 + 2c(\varphi_{i'2} - \varphi_{i'1})$. Setting $c = (4/3)(\varphi_{i'1} - \varphi_{i'2}) > 0$ yields an objective value that is improved by $(1/3)\Gamma/(1 + \Gamma)(\varphi_{i'1} - \varphi_{i'2})$, keeps the variance the same, and now has $\sum_{i=1}^I w_i = I - 2$ or $I - 3$, thus putting us in the regime considered in Case 2.

For any feasible solution where the variance constraint is not binding, the objective value can be improved by changing the values of φ_{i2} such that *none* of them exactly equal φ_{i1} and such that the variance constraint is binding. If this is the case, the worst-case expectation when $\sum_{i=1}^I w_i = I - 1$, μ_{I-1} , can be attained precisely as it was when $\sum_{i=1}^I w_i = 1, \dots, I - 2$ in Case 2 through setting $s = I - 1$ in (4). The variance constraint will be binding, so $\nu_{I-1} = v$.

Case 4. $\sum_{i=1}^I w_i = I$.

Given $\bar{y} \geq \bar{\tau}_0$ as we have assumed, $\sum_{i=1}^I w_i = I$ cannot be a solution, as in this case the constraint imposed by the null cannot be satisfied.

From the four cases considered, we have a total of I candidate values for $\{\mu_s\}$. We now further refine this set. Defining $p = s/I$, we find the largest value in the set $\{\mu_s\}$ through the following optimization problem:

$$\begin{aligned} & \underset{p}{\text{maximize}} \quad \bar{y} + 2 \frac{\Gamma p + 1 - p}{1 + \Gamma} (\bar{\tau}_0 - \bar{y}) \\ & \quad + \frac{\Gamma - 1}{(1 + \Gamma)} \sqrt{p(1 - p) \left(\frac{(1 + \Gamma)^2}{\Gamma} I v - 4(\bar{\tau}_0 - \bar{\tau})^2 \right)} \\ & \text{subject to } p = 0, 1/I, \dots, (I - 1)/I. \end{aligned}$$

Replacing for a moment the domain of p above with $0 \leq p \leq 1$, we have from Lemma 6 that objective function attains its maximum at the value p^* given in (3). As the objective function is concave over the domain $0 \leq p \leq 1$, the $\arg \max$ over the domain $p = 0, 1/I, \dots, (I-1)/I$ is attained at one of the closest grid points to p^* , $\lfloor Ip^* \rfloor / I$ or $\lceil Ip^* \rceil / I$. This yields the indices for s_1 and s_2 of $\lfloor Ip^* \rfloor$ and $\lceil Ip^* \rceil$, yielding the worst-case deviate. From Condition 1, we have that this worst-case deviate yields the worst-case p -value asymptotically, completing the proof.

9.5 Proof of Lemma 3

As a reminder, we are considering favorable situation described in §5.1 where the paired differences Y_i are drawn independently and identically distributed according to a distribution with mean $\bar{\tau}_0$ and variance σ^2 , and there truly is no unmeasured confounding. By the law of large numbers $\bar{y} \rightarrow \bar{\tau}$ and $Iv \rightarrow \sigma^2$ in probability as $I \rightarrow \infty$. The result then follows by noting that if $4\Gamma/(1+\Gamma)^2(\bar{\tau}_0 - \bar{\tau})^2 \leq \sigma^2$, $|\max\{\mu_{s_1}, \mu_{s_2}\} - \mu^*| \rightarrow 0$ and $\mu^* \rightarrow \bar{\tau}_0 + (\sigma/2)(\Gamma - 1)/\sqrt{\Gamma}$ in probability as $I \rightarrow \infty$, where μ^* is defined in (2).

9.6 Proof of Proposition 2

The design sensitivity for the average treatment effect is the solution of $\bar{\tau} = \lim_{I \rightarrow \infty} \max\{\mu_{s_1}, \mu_{s_2}\}$. Supposing that $4\Gamma/(1+\Gamma)^2(\bar{\tau}_0 - \bar{y})^2 \leq \sigma^2$, rearranging the result of Lemma 3 yields that

$$\tilde{\Gamma}_{ate} = \frac{2|\bar{\tau}_0 - \bar{\tau}|\sqrt{\sigma^2 + (\bar{\tau}_0 - \bar{\tau})^2} + \sigma^2 + 2(\bar{\tau}_0 - \bar{\tau})^2}{\sigma^2}$$

To complete the proof, it suffices to show that the value of Γ that solves $4\Gamma/(1+\Gamma)^2(\bar{\tau}_0 - \bar{y})^2 = \sigma^2$ is less than the design sensitivity. Rearranging and solving for Γ yields

$$\Gamma = \frac{2|\bar{\tau}_0 - \bar{\tau}|\sqrt{(\bar{\tau}_0 - \bar{\tau})^2 + \sigma^2} - \sigma^2 + 2(\bar{\tau}_0 - \bar{\tau})^2}{\sigma^2},$$

which is less than $\tilde{\Gamma}_{ate}$ as required.

9.7 Proof of Proposition 3

By corollary 1 of Rosenbaum (2013),

$$\tilde{\Gamma}_{cons} = \frac{\mathbb{E}[|Y_i - \bar{\tau}_0|] + |\bar{\tau} - \bar{\tau}_0|}{\mathbb{E}[|Y_i - \bar{\tau}_0|] - |\bar{\tau} - \bar{\tau}_0|}.$$

Jensen's inequality yields that $|\bar{\tau} - \bar{\tau}_0| \leq \mathbb{E}[|Y_i - \bar{\tau}_0|] \leq \sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2}$. Since $\tilde{\Gamma}_{add}$ is decreasing as a function of $\mathbb{E}[|Y_i - \bar{\tau}_0|]$ on this domain,

$$\tilde{\Gamma}_{cons} \geq \frac{\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} + |\bar{\tau} - \bar{\tau}_0|}{\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} - |\bar{\tau} - \bar{\tau}_0|}.$$

Combining this with the design sensitivity for $\tilde{\Gamma}_{ate}$ given in Proposition 2,

$$\begin{aligned}
& \tilde{\Gamma}_{cons}/\tilde{\Gamma}_{ate} \\
& \geq \sigma^2 \frac{\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} + |\bar{\tau} - \bar{\tau}_0|}{(\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} - |\bar{\tau} - \bar{\tau}_0|)(2|\bar{\tau}_0 - \bar{\tau}|\sqrt{\sigma^2 + (\bar{\tau}_0 - \bar{\tau})^2} + \sigma^2 + 2(\bar{\tau}_0 - \bar{\tau})^2)} \\
& = \sigma^2 \frac{\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} + |\bar{\tau} - \bar{\tau}_0|}{(\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} - |\bar{\tau} - \bar{\tau}_0|)(\sqrt{(\bar{\tau} - \bar{\tau}_0)^2 + \sigma^2} + |\bar{\tau} - \bar{\tau}_0|)^2} \\
& = 1
\end{aligned}$$

9.8 Proof of Proposition 4

The solution of Problem (P1) returns worst-case values of $\varphi_{i2} = r_{Ti2} - r_{Ci1}$. The values of r_{Ti1} and r_{Ci2} are fixed as these are the observed potential outcomes. Suppose $\pi_i = \Gamma/(1 + \Gamma)$. To make it the case that $r_{Ti1} - r_{Ci1} \geq r_{Ti2} - r_{Ci2}$, set $r_{Ti2} = c + \varphi_{i2}$, set $r_{Ci1} = c$, and simply solve for the c such that the two sides are equal. Doing so, we have $r_{Ti1} - c = c + \varphi_{i2} - r_{Ci2} \Rightarrow c = (r_{Ti1} + r_{Ci2} - \varphi_{i2})/2$. For any $c' < c$, $r_{Ti1} - r_{Ci1} \geq r_{Ti2} - r_{Ci2}$ as desired. The proof for $\pi_i = 1/(1 + \Gamma)$ is analogous.

Acknowledgement

The author thanks Dylan Small and Paul Rosenbaum for many helpful conversations about this work.

References

- Bahadur, R. R. and Savage, L. J. (1956). The nonexistence of certain statistical procedures in nonparametric problems. *The Annals of Mathematical Statistics*, 27(4):1115–1122.
- Bertsimas, D. and Tsitsiklis, J. N. (1997). *Introduction to Linear Optimization*, volume 6. Athena Scientific Belmont, MA.
- Ding, P. (2016). A paradox from randomization-based causal inference. *Statistical Science*, to appear.
- Hájek, J. and Šidák, Z. (1967). Theory of Rank Tests.
- Hammond, E. C. (1964). Smoking in relation to mortality and morbidity. findings in first thirty-four months of follow-up in a prospective study started in 1959. *Journal of the National Cancer Institute*, 32(5):1161–1188.
- Heckman, J. J., Urzua, S., and Vytlačil, E. (2006). Understanding instrumental variables in models with essential heterogeneity. *The Review of Economics and Statistics*, 88(3):389–432.
- Hsu, J. Y., Small, D. S., and Rosenbaum, P. R. (2013). Effect modification and design sensitivity in observational studies. *Journal of the American Statistical Association*, 108(501):135–148.

- Hsu, J. Y., Zubizarreta, J. R., Small, D. S., and Rosenbaum, P. R. (2015). Strong control of the familywise error rate in observational studies that discover effect modification by exploratory methods. *Biometrika*, 102(4):767–782.
- Imai, K. (2008). Variance identification and efficiency analysis in randomized experiments under the matched-pair design. *Statistics in medicine*, 27(24):4857–4873.
- Imbens, G. W. (2004). Nonparametric estimation of average treatment effects under exogeneity: A review. *Review of Economics and Statistics*, 86(1):4–29.
- Jick, H., Miettinen, O. S., Neff, R. K., Shapiro, S., Heinonen, O. P., and Slone, D. (1973). Coffee and myocardial infarction. *New England Journal of Medicine*, 289(2):63–67.
- Neyman, J. (1923). On the application of probability theory to agricultural experiments. Essay on principles. Section 9 (in Polish). *Roczniki Nauk Rolniczych*, X:1–51. Reprinted in *Statistical Science*, 1990, 5(4):463–480.
- Rosenbaum, P. R. (1987). Sensitivity analysis for certain permutation inferences in matched observational studies. *Biometrika*, 74(1):13–26.
- Rosenbaum, P. R. (2002a). Covariance adjustment in randomized experiments and observational studies. *Statistical Science*, 17(3):286–327.
- Rosenbaum, P. R. (2002b). *Observational Studies*. Springer, New York.
- Rosenbaum, P. R. (2004). Design sensitivity in observational studies. *Biometrika*, 91(1):153–164.
- Rosenbaum, P. R. (2005). Heterogeneity and causality. *The American Statistician*, 59(1):147–152.
- Rosenbaum, P. R. (2007). Sensitivity analysis for M-estimates, tests, and confidence intervals in matched observational studies. *Biometrics*, 63(2):456–464.
- Rosenbaum, P. R. (2010). *Design of Observational Studies*. Springer, New York.
- Rosenbaum, P. R. (2013). Impact of multiple matched controls on design sensitivity in observational studies. *Biometrics*, 69(1):118–127.
- Rosenbaum, P. R. (2015). Bahadur efficiency of sensitivity analyses in observational studies. *Journal of the American Statistical Association*, 110(509):205–217.
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66(5):688–701.
- Werfel, U., Langen, V., Eickhoff, I., Schoonbrood, J., Vahrenholz, C., Brauksiepe, A., Popp, W., and Norporth, K. (1998). Elevated dna single-strand breakage frequencies in lymphocytes of welders exposed to chromium and nickel. *Carcinogenesis*, 19(3):413–418.